HIDRADENITIS SUPPURATIVA (HS)

This study tests a new drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and abscesses. The main goal is to see if the drug can reduce the number of inflamed bumps by at least 75% after 16 weeks. Partici…

This study tests a new drug called tibulizumab for adults with hidradenitis suppurativa (HS), a painful skin condition that causes boils and tunnels. About 225 people will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 weeks. The goa…

This study tests whether high-dose radiotherapy can provide lasting relief for people with moderate to severe hidradenitis suppurativa (HS) that hasn't responded to other treatments. Ten adults with HS in both armpits will receive radiation to one armpit while the other continues…

This study tests a new drug called BFB759 in 210 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants receive either BFB759 or a placebo for up to 40 weeks to see if the drug reduces abscesses and inflammatory bumps. The goal is to …

This study is for people with hidradenitis suppurativa who have already completed a previous trial of the drug povorcitinib and saw benefits. It aims to provide continued treatment while monitoring long-term safety and how well the drug controls symptoms like abscesses and inflam…

This study tests whether NAV-240 can reduce painful skin bumps and draining tunnels in people with moderate-to-severe hidradenitis suppurativa (HS). About 150 adults will receive either NAV-240 or a placebo through an IV drip. The main goal is to see if NAV-240 leads to a 75% red…

This study tests whether CIT-013 can reduce disease activity in adults with hidradenitis suppurativa, a painful skin condition. About 96 participants will receive either 50 mg, 100 mg, or a placebo every two weeks for 12 weeks. Researchers will compare symptom improvement and tra…

This program provides secukinumab (AIN457) to people with hidradenitis suppurativa who have no other treatment options. It is for patients with serious disease who cannot join a clinical trial or use approved therapies. Doctors must request access for their patients.

This study tests an experimental drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and tunnels under the skin. The goal is to see if the drug is safe, how the body processes i…

This study tests a medicated foam (roflumilast) applied to the skin for treating hidradenitis suppurativa (HS), a condition causing painful lumps. Researchers want to see if it reduces the number of abscesses and inflamed nodules over 16 weeks. The study involves 20 adults with m…

This study looks at two wound dressings used after surgery for hidradenitis suppurativa (HS), a painful skin condition. The newer dressing, Pelashield™ PainGuard™, contains silver to fight bacteria and lidocaine to reduce pain. It will be compared to the standard Restrata® dressi…

This study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are after starting a medication called secukinumab (Cosentyx). Researchers will ask about 77 adults in Saudi Arabia about their treatment experience and quality of life over 24 weeks. T…

This study tests whether a 1726-nm laser can safely reduce painful lumps and abscesses in people with mild-to-moderate hidradenitis suppurativa (HS). Thirty adults with HS on both sides of their body will receive real laser on one side and a fake treatment on the other. The goal …

This study monitors up to 36 people who previously received an experimental gene-modified Treg therapy for rheumatoid arthritis or hidradenitis suppurativa. Researchers will watch for delayed side effects, how long the modified cells last in the body, and any serious health event…